Observational studyJapanese journal of ophthalmology2026
Treatment outcomes of patients with neovascular age-related macular degeneration after switching from aflibercept to faricimab.
Observational study in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeovascular age-related macular degeneration (nAMD) can cause vision loss and irreversible blindness. However, its treatment needs to be improved. This study aimed to evaluate the 1-year treatment outcomes in patients with nAMD after switching from 2 mg aflibercept to faricimab. STUDY
designRetrospective observational study.
methodsWe included 83 eyes of 83 patients with nAMD who switched from 2 mg aflibercept to faricimab to extend the administration interval or eliminate exudative changes, with ≥ 1 year of follow-up. We retrospectively examined the 1-year treatment outcomes after switching, with the time of switching as the baseline.
resultsAfter switching, the mean log minimum angle of resolution best corrected visual acuity was significantly improved from 0.35 to 0.33 (p = 0.0498), and the mean central retinal thickness was significantly reduced from 302 μm to 237 μm (p < 0.0001). A significant reduction was observed in the incidence of subretinal fluid, intraretinal fluid, and subretinal pigment epithelial fluid (p < 0.05). The mean dosing interval was significantly extended from 5.58 weeks to 9.69 weeks (p < 0.0001). One year after switching, 66 eyes (80%) continued receiving faricimab, while 17 eyes (20%) were switched to other drugs owing to worsening exudation or other reasons.
conclusionOne year after switching treatment for nAMD from 2 mg aflibercept to faricimab, visual acuity and macular morphology were improved, and the treatment interval was extended. The study's findings could help develop strategies for improving nAMD.
Indexed as
Identifiers
41091318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.